- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00977132
Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome (VALENA)
Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment will be administered as continuous therapy, i.e. it should be taken on each day as described below without treatment interruption as long as no criteria for termination of treatment are met. After two years the primary endpoint will be evaluated. Non-responders will be taken off study after 4 months of therapy. Patients who relapse after an initial response to study treatment can receive one attempt to re-start therapy after a short duration of discontinuation.
Treatment with Valproic Acid starts at day 1. The dose of Valproic Acid is slowly increased. In the morning of day 13 trough level of Valproic Acid will be checked. The target range will be 50-110 µg/l. The dose of Valproic Acid will be adjusted depending on the trough level.
In the first eight weeks of therapy weekly controls of Valproic Acid levels are required. Thereafter, Valproic Acid levels will be checked every four weeks.
The planned dose of lenalidomide is 10 mg/day, orally as continuous therapy. Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal. In the course of the study the dose will be adjusted to the results of the blood count.
Only one cycle of study drug (28 days) will be supplied to the patient every four weeks.
Patients experiencing adverse events may need study treatment modifications.
During treatment with study medication weekly control visits for the detection of adverse events are required during the first eight weeks, thereafter the patient must be seen every four weeks.
Therapeutic success is evaluated in 4-weekly intervals. Bone marrow will be examined after 12 weeks and after 48 weeks or in case of premature study termination
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Baden Würtemberg
-
Freiburg, Baden Würtemberg, Germany, 79106
- Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizini
-
-
Bayern
-
Ulm, Bayern, Germany, 89081
- Universitätsklinikum Ulm, Klinik für Innere Medizin III
-
-
NRW
-
Duesseldorf, NRW, Germany, 40225
- Heinrich-Heine-University Duesseldorf, Department of Hematology, Oncology and Clinical Immunology
-
Duisburg, NRW, Germany, 47166
- St. Johannes Hospital Duisburg
-
-
Niedersachsen
-
Goettingen, Niedersachsen, Germany, 37075
- Georg-August-Universität,Universitätsklinikum - Abteilung Hämatologie und Onkologie
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- Universitätsklinikum Carl Gustav Carus an der TU Dresden, Medizinische Klinik und Poliklinik I
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cytologically/histologically confirmed primary myelodysplastic syndrome (pMDS) with a favorable risk profile, i.e., low or intermediate I risk group according to IPSS (<10% blasts, no unfavorable karyotype)
- platelet count ≥50.000/µl
- absolute neutrophil count ≥1.000/µl
- age ≥18 years at the time of signing the informed consent form
- Karnofsky performance status > 50%
- written informed consent to participate
- erythropoietin level > 200 mU/ml or failure of previous therapy with erythropoietin
- patients in whom allogeneic bone marrow transplantation, treatment with growth factors or immune therapy is not possible due to medical or biologic reasons or patients in whom such a therapy would be possible but who do not agree to such a therapy for personal reasons
- females of childbearing potential (FCBP, see page 23) must agree to one reliable form of contraception or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 4 weeks before starting study drug; 2) while participating in the study, even during treatment interruptions; and 3) for at least 4 weeks after discontinuation from the study.
Exclusion Criteria:
- patients with 5q deletion
- MDS treated with experimental therapy or chemotherapy within 4 weeks prior to start of treatment with study drugs
- previous treatment of MDS with valproic acid or lenalidomide as monotherapy patients suitable for chemotherapy, therapy with growth factors or allogeneic bone marrow transplantation and who are willing to start such a therapy
- hypersensitivity to thalidomide
- insufficient liver function (bilirubin, AST or ALT > 2 x ULN)
- hepatic disease [details see full protocol]
- markedly impaired renal function (serum creatinine > 2mg/dl)
- pregnancy, breast feeding, lactation, refusal to use safe contraceptive methods during the study
- psychiatric disease or addiction with impaired ability to act and make decisions according to one's free will
- participation in another interventional study 4 weeks prior to or during this study
- known hypersensitivity or allergies to one of the study drugs or their ingredients
- plasmatic coagulation disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lenalidomide
Lenalidomid in combination valproic acid
|
Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme day morning dose midday dose evening dose contents of 1 tablet 1+2 0 0 1 500 mg 3+4 ½ 0 1 500 mg 5+6 1 0 1 500 mg 7+8 1 ½ 1 500 mg 9+10 1 1 1 500 mg 11+12 1 1 1 500 mg In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks. 5 mg/day, continuous therapy Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal. Only one cycle of study drug (28 days) will be supplied to the patient every four weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
hematologic success
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
overall survival
Time Frame: 5 years
|
5 years
|
Progression free survival
Time Frame: 5 years
|
5 years
|
toxicity and safety
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Investigators
- Study Director: Norbert Gattermann, Professor, Department of Hematology, Oncology and Clinical Immunology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Preleukemia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- Valena-Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome MDS
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
-
PersImmune, IncUniversity of California, San DiegoUnknown
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on Valproic aicd
-
Williams LifeSkillsDuke UniversityCompletedFocus Whether After Implant Pre-AICD Video Was HelpfulUnited States
-
Taipei Veterans General Hospital, TaiwanUnknownOsteoarthritis, KneeTaiwan
-
New Mexico Cancer Care AllianceCompleted
-
St. Luke's-Roosevelt Hospital CenterMontefiore Medical CenterCompletedHeart Failure | Cardiac Resynchronization TherapyUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell LymphomaUnited States
-
New Mexico Cancer Care AllianceWithdrawnChronic Myelogenous LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System TumorsCanada, United States